|
1）Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365: 147-56
|
|
|
|
2）Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009; 137: 2105-11
|
|
|
|
|
|
3）Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006; 101: 1524-8; quiz 680
|
|
|
|
|
|
4）Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiol-ogical and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007; 138: 534-40
|
|
|
|
|
|
5）Saenko EL, Yakhyaev AV, Mikhailenko I, et al. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999; 274: 37685-92
|
|
|
|
|
|
6）Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010; 362: 823-32
|
|
|
|
|
|
7）de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53: 762-8
|
|
|
|
|
|
8）Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006; 44: 1039-46
|
|
|
|
|
|
9）Rijken DC, Kock EL, Guimaraes AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012; 10: 2116
|
|
|
|
|
|
10）Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011; 9: 1713-23
|
|
|
|
|
|
11）Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology. 2010; 52: 249-55
|
|
|
|
|
|
12）Sogaard KK, Horvath-Puho E, Gronbaek H, et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009; 104: 96-101
|
|
|
|
|
|
13）Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012; 57: 203-12
|
|
|
|
|
|
14）Huard G, Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. Int J Hepatol. 2012; in press (doi; 10. 1155/2012/672986)
|
|
|
|
|
|
15）Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anti-coagulants, and when and how to switch. Blood. 2012; 119: 3016-23
|
|
|
|
|
|
16）Anstee QM, Goldin RD, Wright M, et al. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost. 2008; 6: 1336-43
|
|
|
|
|
|
17）Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012; 109: E2165-72
|
|
|
|
|